Coya Therapeutics Past Earnings Performance
Past criteria checks 0/6
Coya Therapeutics's earnings have been declining at an average annual rate of -24.9%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 141.9% per year.
Key information
-24.9%
Earnings growth rate
17.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 141.9% |
| Return on equity | -33.4% |
| Net Margin | -112.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Companies Like Coya Therapeutics (NASDAQ:COYA) Can Afford To Invest In Growth
Oct 29
Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts
Oct 13Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans
Mar 26Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal
Feb 13Coya Therapeutics: Interesting Early Data In CNS Diseases, Very Low Cash Position
Jan 13We Think Coya Therapeutics (NASDAQ:COYA) Needs To Drive Business Growth Carefully
Sep 06Here's Why We're Watching Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation
May 17Revenue & Expenses Breakdown
How Coya Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 10 | -11 | 9 | 0 |
| 30 Jun 24 | 10 | -10 | 9 | 0 |
| 31 Mar 24 | 6 | -10 | 9 | 0 |
| 31 Dec 23 | 6 | -8 | 8 | 0 |
| 30 Sep 23 | 0 | -12 | 6 | -4 |
| 30 Jun 23 | 0 | -13 | 6 | -2 |
| 31 Mar 23 | 0 | -13 | 6 | -1 |
| 31 Dec 22 | 0 | -12 | 5 | 0 |
| 30 Sep 22 | 0 | -11 | 5 | 5 |
| 30 Jun 22 | 0 | -8 | 4 | 4 |
| 31 Mar 22 | 0 | -6 | 3 | 3 |
| 31 Dec 21 | 0 | -5 | 2 | 3 |
Quality Earnings: COYA is currently unprofitable.
Growing Profit Margin: COYA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: COYA is unprofitable, and losses have increased over the past 5 years at a rate of 24.9% per year.
Accelerating Growth: Unable to compare COYA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: COYA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: COYA has a negative Return on Equity (-33.42%), as it is currently unprofitable.